M.D. Anderson Cancer Center
To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Primary Objectives: To determine the safety and efficacy of mosunetuzumab in combination with zanubrutinib as determined by best complete response (CR) rate of combination treatment for patients with relapsed or refractory marginal zone lymphoma (MZL). Secondary Objectives: To determine best overall response rate (ORR), duration of response (DOR), time to next treatment, progression-free survival (PFS), overall survival (OS), and evaluation of tolerability of mosunetuzumab and zanubrutinib as treatment for patients with relapsed/refractory MZL. Exploratory Objective: To determine the impa…
Inclusion Criteria: Patients must meet the following criteria for study entry: 1. Histologically diagnosed marginal zone lymphoma (any subtypes) o Low grade or indolent B-cell lymphoma unclassifiable is also eligible 2. Have received at least 1 prior treatment including CD20 monoclonal antibody 3. Patients have relapsed or refractory disease to their most recent regimen 4. Stage II, III or IV disease 5. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of mosunetuzumab and zanubrutinib combination in patients \<18 years of age, children are exclude…
Given by IV
Given by IV
Arctuva estimate
Verify or correct the compensation shown for this listing.